✦ LIBER ✦

Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer

✍ Scribed by Tang, Chuanhao; Gao, Hongjun; Li, Xiaoyan; Liu, Yi; Li, Jianjie; Qin, Haifeng; Wang, Weixia; Qu, Lili; An, Juan; Yang, Shaoxing; Liu, Xiaoqing

Book ID: 121553227
Publisher: Springer-Verlag
Year: 2014
Tongue: English
Weight: 350 KB
Volume: 140
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-014-1582-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epidermal growth factor receptor tyrosin

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues

✍ K. Bencardino; M. Manzoni; S. Delfanti; A. Riccardi; M. Danova; G. R. Corazza 📂 Article 📅 2007 🏛 Springer Milan 🌐 English ⚖ 117 KB

Prospective Study of Epidermal Growth Fa

Prospective Study of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Concurrent With Individualized Radiotherapy for Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

✍ Jing Wang; Ting-Yi Xia; Ying-Jie Wang; Hong-Qi Li; Ping Li; Ji-Dong Wang; Dong-S 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 184 KB

SAA1 is over-expressed in plasma of non

SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors

✍ Milan, Enrico; Lazzari, Chiara; Anand, Santosh; Floriani, Irene; Torri, Valter; 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 791 KB

EKB-569, a new irreversible epidermal gr

EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib

✍ Yoshimura, Naruo; Kudoh, Shinzoh; Kimura, Tatsuo; Mitsuoka, Shigeki; Matsuura, K 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Do We Really Need Another Epidermal Grow

Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non-Small-Cell Lung Cancer and EGFR Mutations?

✍ Haspinger, E. R.; Garassino, M. C.; Torri, V.; Cinquini, M.; De Braud, F.; Gelso 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 78 KB

KRAS Mutation Is an Important Predictor

KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer

✍ Massarelli, E.; Varella-Garcia, M.; Tang, X.; Xavier, A. C.; Ozburn, N. C.; Liu, 📂 Article 📅 2007 🏛 American Association for Cancer Research 🌐 English ⚖ 196 KB